Want to see EWTX full AI Analyst Report?
EWTX Stock Chart & Stats
$34.43
-$0.39(-1.54%)
At close: 4:00 PM EST
$34.43
-$0.39(-1.54%)
Day’s Range― - ―
52-Week Range$12.30 - $48.40
Previous CloseN/A
Volume107.81K
Average Volume (3M)1.70M
Market Cap
$5.20B
Enterprise Value$3.72B
Total Cash (Recent Filing)$499.56M
Total Debt (Recent Filing)$3.79M
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Aug 06, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.66
Shares Outstanding107,593,000
10 Day Avg. Volume1,286,791
30 Day Avg. Volume1,695,604
Financial Highlights & Ratios
PEG Ratio-1.23
Price to Book (P/B)4.89
Price to Sales (P/S)0.00
P/FCF Ratio-17.76
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.30K
Enterprise Value/Ebitda-21.12
Forecast
1Y Price Target
$50.60Price Target Upside46.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-1.96
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetEdgewise's extremely low debt and sizable equity provide durable financial runway to fund clinical programs and R&D without immediate refinancing risk. This balance-sheet strength increases optionality for partnerships, milestone-driven payments, or targeted M&A, supporting long-term strategy execution.
Sale Provides Major Funding BoostThe definitive sale of sevasemten unlocks substantial upfront cash and milestone potential, immediately improving liquidity and reducing near-term financing needs. This structural capital infusion allows reallocation of resources to prioritized cardiovascular programs and de-risks funding for key development stages.
Focused Cardiovascular Pipeline & Upcoming ReadoutRefocusing on EDG-7500 and EDG-15400 concentrates R&D on a clearer therapeutic area and near-term catalysts. A Phase 2 CIRRUS-HCM readout is a durable de-risking milestone: positive data could validate the franchise, enable partnerships or approval pathways, and create sustainable value beyond one-off asset sales.
Bears Say
Pre-revenue OperationsEdgewise has no commercial revenue, so long-term value depends entirely on clinical and regulatory success or licensing outcomes. That structural pre-revenue profile creates binary program risk, extends cash runway dependence, and delays any sustainable internal cash generation from product sales.
High And Persistent Cash BurnSustained negative operating and free cash flows indicate the company continues to consume capital to fund trials and operations. Even with recent asset-sale proceeds, persistent burn could force future financings, program prioritization, or dilution if milestones or partnerships don't materialize as planned.
Widening Losses & Negative ROEMaterial and growing net losses alongside deeply negative ROE show the company's capital is being eroded by operations. Over time this undermines shareholder value absent clinical successes, and indicates that operational efficiency and return generation remain significant structural challenges to sustainable growth.
Edgewise Therapeutics News
EWTX FAQ
What was Edgewise Therapeutics, Inc.’s price range in the past 12 months?
Edgewise Therapeutics, Inc. lowest stock price was $12.30 and its highest was $48.40 in the past 12 months.
What is Edgewise Therapeutics, Inc.’s market cap?
Edgewise Therapeutics, Inc.’s market cap is $5.20B.
When is Edgewise Therapeutics, Inc.’s upcoming earnings report date?
Edgewise Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were Edgewise Therapeutics, Inc.’s earnings last quarter?
Edgewise Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.485 by $0.025.
Is Edgewise Therapeutics, Inc. overvalued?
According to Wall Street analysts Edgewise Therapeutics, Inc.’s price is currently Undervalued.
Does Edgewise Therapeutics, Inc. pay dividends?
Edgewise Therapeutics, Inc. does not currently pay dividends.
What is Edgewise Therapeutics, Inc.’s EPS estimate?
Edgewise Therapeutics, Inc.’s EPS estimate is -0.47.
How many shares outstanding does Edgewise Therapeutics, Inc. have?
Edgewise Therapeutics, Inc. has 107,593,000 shares outstanding.
What happened to Edgewise Therapeutics, Inc.’s price movement after its last earnings report?
Edgewise Therapeutics, Inc. reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.485. Following the earnings report the stock price went down -3.812%.
Which hedge fund is a major shareholder of Edgewise Therapeutics, Inc.?
Currently, no hedge funds are holding shares in EWTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edgewise Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.60 (46.96% Upside)
$50.60 (46.96% Upside)
Blogger Sentiment
Bullish
EWTX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 522.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 11.6%
Last 30 Days ▲ 15.5%
Last 30 Days ▲ 15.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
243.15%
12-Months-Change
Fundamentals
Return on Equity
-32.55%
Trailing 12-Months
Asset Growth
14.11%
Trailing 12-Months
Company Description
Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
EWTX Stock 12 Month Forecast
Average Price Target
$50.60
▲(46.96% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Vera Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
0.94% Insiders
13.90% Mutual Funds
0.02% Other Institutional Investors
75.64% Public Companies and
Individual Investors